Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013

被引:2
|
作者
Ponizovsky, Alexander M. [1 ]
Marom, Eli [2 ]
Ben-Laish, Michal [2 ]
Barash, Igor [1 ]
Weizman, Abraham [3 ,4 ]
Schwartzberg, Eyal [2 ]
机构
[1] Minist Hlth, Mental Hlth Serv, Jerusalem, Israel
[2] Minist Hlth, Pharmaceut Adm, Jerusalem, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Geha Mental Hlth Ctr, Res Unit, Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Felsenstein Med Res Ctr, Tel Aviv, Israel
来源
ISRAEL JOURNAL OF HEALTH POLICY RESEARCH | 2016年 / 5卷
关键词
Atypical antipsychotics; Typical antipsychotics; Sertindole; Ziprasidone; Clozapine; Olanzapine; Quetiapine; Amisulpride; Risperidone; Aripiprazole; Paliperidone; Iloperidone; Pharmacoepidemiology; DOUBLE-BLIND; ATYPICAL ANTIPSYCHOTICS; CHRONIC-SCHIZOPHRENIA; HALOPERIDOL; MEDICATION; DRUGS; METAANALYSIS; CONSUMPTION; RISPERIDONE; DEPRESSION;
D O I
10.1186/s13584-016-0074-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Although serious mental illneses are treated with both typical and atypical antipsychotic grugs, trends in their use in psychiatric inpatient population in Israel are unrecognized. The aim of this study was to detect trends in the use of typical and atypical antipsychotic drugs in the Israeli inpatient psychiatric population throughout the last decade. Methods: Data regarding allocation of typical and atypical antipsychotics, over the period 2004 to 2013, were extracted from the electronic records of SAREL, Israel's largest private supplier of drugs to healthcare and medical facilities. The data were converted to defined daily doses (DDD) per 1000 inpatients per day. Results: Usage of the ten atypical antipsychotic agents allocated through Israel's national health care system increased by 73 %, from 128.09 DDD/1000 inpatients/day in 2004 to 221.69 DDD/1000 inpatients/day in 2013. This rise from 2004 to 2013 was largely due to a 1.6-fold increase in the administration of olanzapine (48.31 to 79.57 DDD/1000 inpatients/day), a 4.4-fold increase of quetiapine (9.74 to 43.04 DDD/1000 inpatients/day) and 3.7-fold increase of amisulpride (5.54 to 20.38 DDD/1000 inpatients/day). At the same period, the total utilization of 12 main typical antipsychotics decreased by 15.5 %, from 148.67 DDD/1000 inpatients/day in 2004 to 125.57 DDD/1000 inpatients/day in 2013. Over the entire period, total DDDs of both classes of antipsychotics (typical and atypical) increased by 38 %. Conclusions: Similar to trends in the treatment of psychiatric outpatients in other countries, there was a substantial increase in the administration of atypical antipsychotic drugs to the Israeli psychiatric inpatient population across the study period. A decrease in the use of typical antipsychotics (substitution), polypharmacy, administration for more indications (supplementation) and the use of larger doses of antipsychotics may account, in part, for this increase. The findings have implications for mental health policy in the context of the Mental Health Care System Reform. Systematic studies on appropriate dosing of antipsychotics and augmentation strategies are warranted.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Trends in the use of antipsychotics in the Israeli inpatient population, 2004–2013
    Alexander M. Ponizovsky
    Eli Marom
    Michal Ben-Laish
    Igor Barash
    Abraham Weizman
    Eyal Schwartzberg
    Israel Journal of Health Policy Research, 5
  • [2] Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013
    Forrester, T.
    Siskind, D.
    Winckel, K.
    Wheeler, A.
    Hollingworth, S.
    PHARMACOPSYCHIATRY, 2015, 48 (4-5) : 164 - 169
  • [3] Antidepressant drug use among adolescents during 2004-2013: a population-based register linkage study
    Hartz, I.
    Skurtveit, S.
    Hjellvik, V.
    Furu, K.
    Nesvag, R.
    Handal, M.
    ACTA PSYCHIATRICA SCANDINAVICA, 2016, 134 (05) : 420 - 429
  • [4] Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users
    Montastruc, Francois
    Benard-Laribiere, Anne
    Noize, Pernelle
    Pambrun, Elodie
    Diaz-Bazin, Fabienne
    Tournier, Marie
    Begaud, Bernard
    Pariente, Antoine
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (05) : 619 - 626
  • [5] “Off-Label Use” of Second Generation Antipsychotics in an Austrian Inpatient Population — Data from the Austrian AMSP
    A. Konstantinidis
    U. Moser
    A. Kutzelnigg
    R. Grohmann
    R. Engel
    S. Kasper
    Drug Safety, 2008, 31 : 885 - 885
  • [6] Off-Label Use of Second Generation Antipsychotics in an Austrian Inpatient Population - Data from the Austrian AMSP
    Konstantinidis, A.
    Moser, U.
    Kutzelnigg, A.
    Grohmann, R.
    Engel, R.
    Kasper, S.
    DRUG SAFETY, 2008, 31 (10) : 952 - 953
  • [7] Use of Psychopharmaceuticals in the Northeastern Argentine Region during the decade of 2004-2013
    Abraham Fridman, Gerardo
    ARS PHARMACEUTICA, 2018, 59 (03) : 113 - 120
  • [8] Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users
    François Montastruc
    Anne Bénard-Laribière
    Pernelle Noize
    Elodie Pambrun
    Fabienne Diaz-Bazin
    Marie Tournier
    Bernard Bégaud
    Antoine Pariente
    European Journal of Clinical Pharmacology, 2018, 74 : 619 - 626
  • [9] Changes in hazardous drinking in Spanish adolescent population in the last decade (2004-2013) using a quantitative and qualitative design
    Perez-Milena, Alejandro
    de Dios Redondo-Olmedilla, Manuel
    Luz Martinez-Fernandez, Maria
    Jimenez-Pulido, Idoia
    Mesa-Gallardo, Inmaculada
    Javier Leal-Helmling, Francisco
    ATENCION PRIMARIA, 2017, 49 (09): : 525 - 533
  • [10] Clinical depression and anxiety among ST-elevation myocardial infarction hospitalizations: Results from Nationwide Inpatient Sample 2004-2013
    Pino, Elizabeth C.
    Zuo, Yi
    Borba, Christina P. C.
    Henderson, David C.
    Kalesan, Bindu
    PSYCHIATRY RESEARCH, 2018, 266 : 291 - 300